BioDelivery Sciences International Inc
F:BD5
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Nongshim Co Ltd
KRX:004370
|
KR |
BioDelivery Sciences International Inc
Total Current Liabilities
BioDelivery Sciences International Inc
Total Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
B
|
BioDelivery Sciences International Inc
F:BD5
|
Total Current Liabilities
$82.4m
|
CAGR 3-Years
56%
|
CAGR 5-Years
34%
|
CAGR 10-Years
N/A
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Total Current Liabilities
$54.1B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
5%
|
CAGR 10-Years
7%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Total Current Liabilities
$23.4B
|
CAGR 3-Years
2%
|
CAGR 5-Years
4%
|
CAGR 10-Years
11%
|
|
|
Pfizer Inc
NYSE:PFE
|
Total Current Liabilities
$37B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
7%
|
CAGR 10-Years
2%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Total Current Liabilities
$28.3B
|
CAGR 3-Years
5%
|
CAGR 5-Years
1%
|
CAGR 10-Years
4%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Total Current Liabilities
$35.2B
|
CAGR 3-Years
27%
|
CAGR 5-Years
23%
|
CAGR 10-Years
16%
|
|
BioDelivery Sciences International Inc
Glance View
BioDelivery Sciences International, Inc. operates as a pharmaceutical company, which engages in the development and commercialization of new applications of approved therapeutics to address important unmet medical needs. The company is headquartered in Raleigh, North Carolina and currently employs 200 full-time employees. The company went IPO on 2002-06-25. The firm focuses on delivering therapies for individuals living with serious and debilitating chronic conditions. The Compnay builts a portfolio of products that includes utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA), drug-delivery technology to develop and commercialize new applications of therapies aimed at addressing important unmet medical needs. BEMA drug delivery technology consists of a small, bi-layered erodible polymer film for application to the buccal mucosa (the lining inside the cheek). The firm's product candidates includes BELBUCA (buprenorphine buccal film), CIII, for Chronic Pain; Symproic (naldemedine), for Opioid Induced Constipation and ONSOLIS (fentanyl buccal soluble film) for Breakthrough Cancer Pain.
See Also
What is BioDelivery Sciences International Inc's Total Current Liabilities?
Total Current Liabilities
82.4m
USD
Based on the financial report for Dec 31, 2021, BioDelivery Sciences International Inc's Total Current Liabilities amounts to 82.4m USD.
What is BioDelivery Sciences International Inc's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 5Y
34%
Over the last year, the Total Current Liabilities growth was 55%. The average annual Total Current Liabilities growth rates for BioDelivery Sciences International Inc have been 56% over the past three years , 34% over the past five years .
